Tina B. Lonsdorf

Tina B. Lonsdorf

Auto-generated profile, based on publicly available information

Tina B. Lonsdorf

University of Bielefeld

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
TLTina B. Lonsdorf
Tina B. Lonsdorf
MMMareike M. Menz
Mareike M. Menz
MAMarta Andreatta
Marta Andreatta
MFMiguel A. Fullana
Miguel A. Fullana
AGArmita Golkar
Armita Golkar
CMChristian J. Merz
Christian J. Merz
The so-called 'replicability crisis' has sparked methodological discussions in many areas of science in general, and in psychology in particular. This has led to recent endeavours to promote the transparency, rigour, and ultimately, replicability of research. Originating from this zeitgeist, the challenge to discuss critical issues on terminology, design, methods, and analysis considerations in fear conditioning research is taken up by this work, which involved representatives from fourteen of the major human fear conditioning laboratories in Europe. This compendium is intended to provide a basis for the development of a common procedural and terminology framework for the field of human fear conditioning. Whenever possible, we give general recommendations. When this is not feasible, we provide evidence-based guidance for methodological decisions on study design, outcome measures, and analyses. Importantly, this work is also intended to raise awareness and initiate discussions on crucial questions with respect to data collection, processing, statistical analyses, the impact of subtle procedural changes, and data reporting specifically tailored to the research on fear conditioning.

7 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGArmita Golkar
Armita Golkar
TLTina B. Lonsdorf
Tina B. Lonsdorf
AOAndreas Olsson
Andreas Olsson
KLKara M. Lindstrom
Kara M. Lindstrom
JBJonathan Berrebi
Jonathan Berrebi
AÖArne Öhman
Arne Öhman
The lateral prefrontal and orbitofrontal cortices have both been implicated in emotion regulation, but their distinct roles in regulation of negative emotion remain poorly understood. To address this issue we enrolled 58 participants in an fMRI study in which participants were instructed to reappraise both negative and neutral stimuli. This design allowed us to separately study activations reflecting cognitive processes associated with reappraisal in general and activations specifically related to reappraisal of negative emotion. Our results confirmed that both the dorsolateral prefrontal cortex (DLPFC) and the lateral orbitofrontal cortex (OFC) contribute to emotion regulation through reappraisal. However, activity in the DLPFC was related to reappraisal independently of whether negative or neutral stimuli were reappraised, whereas the lateral OFC was uniquely related to reappraisal of negative stimuli. We suggest that relative to the lateral OFC, the DLPFC serves a more general role in emotion regulation, perhaps by reflecting the cognitive demand that is inherent to the regulation task.

1 February 2009 in Psychological Science
Verified
Journal Article
Closed access
TLTina B. Lonsdorf
Tina B. Lonsdorf
AWAlmut I. Weike
Almut I. Weike
PNPernilla Nikamo
Pernilla Nikamo
MSMartin Schalling
Martin Schalling
AHAlfons O. Hamm
Alfons O. Hamm
AÖArne Öhman
Arne Öhman


15 August 2014 in Learning & Memory
Verified
Journal Article
Open access
PDF file
JHJan Haaker
Jan Haaker
AGArmita Golkar
Armita Golkar
DHDirk Hermans
Dirk Hermans
TLTina B. Lonsdorf
Tina B. Lonsdorf
In human research, studies of return of fear (ROF) phenomena, and reinstatement in particular, began only a decade ago and recently are more widely used, e.g., as outcome measures for fear/extinction memory manipulations (e.g., reconsolidation). As reinstatement research in humans is still in its infancy, providing an overview of its stability and boundary conditions and summarizing methodological challenges is timely to foster fruitful future research. As a translational endeavor, clarifying the circumstances under which (experimental) reinstatement occurs may offer a first step toward understanding relapse as a clinical phenomenon and pave the way for the development of new pharmacological or behavioral ways to prevent ROF. The current state of research does not yet allow pinpointing these circumstances in detail and we hope this review will aid the research field to advance in this direction. As an introduction, we begin with a synopsis of rodent work on reinstatement and theories that have been proposed to explain the findings. The review however mainly focuses on reinstatement in humans. We first describe details and variations of the experimental setup in reinstatement studies in humans and give a general overview of results. We continue with a compilation of possible experimental boundary conditions and end with the role of individual differences and behavioral and/or pharmacological manipulations. Furthermore, we compile important methodological and design details on the published studies in humans and end with open research questions and some important methodological and design recommendations as a guide for future research.

10 June 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JHJan Haaker
Jan Haaker
SGStefano Gaburro
Stefano Gaburro
ASAnupam Sah
Anupam Sah
NGNina Gartmann
Nina Gartmann
TLTina B. Lonsdorf
Tina B. Lonsdorf
RKRaffael Kalisch
Raffael Kalisch
Significance: Traumatic events can engender persistent excessive fear responses to trauma reminders that may return even after successful treatment. In the psychotherapy of fear or anxiety disorders, patients make safety experiences that generate fear-inhibitory safety memories. Fear, however, frequently returns because safety memory retrieval fails. We find that safety memories can be strengthened and are more easily retrieved when adding a standard anti-Parkinson drug that augments brain levels of the neurotransmitter dopamine directly after a safety experience. In mice and humans, this treatment up-regulates an anti-fear area in the frontal cortex. Our findings open a unique avenue for improving psychotherapy.